Status:
COMPLETED
Adaptive Dose-Escalated Multi-modality Image-guided RadiothErapy
Lead Sponsor:
The Netherlands Cancer Institute
Conditions:
Head and Neck Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Patients with primary head and neck squamous cell carcinoma (HNSCC) planned for treatment with radiotherapy with or without chemotherapy in curative setting will be treated with an adaptive radiothera...
Detailed Description
If there is a complete metabolic response on the FDG-PET after 2 weeks, the entire tumor will receive 70 Gy. If there is a complete metabolic response after 4 weeks of treatment, the residual FDG-avid...
Eligibility Criteria
Inclusion
- Histologic biopsy confirmed squamous cell carcinoma of the oral cavity, HPV-negative oropharynx, HPV-positive oropharynx with a minimum of 10 pack-years, hypopharynx or larynx
- T2-T4
- Scheduled for radiotherapy or radiotherapy with cisplatin or cetuximab
Exclusion
- GFR\<30
- Other neoplasms with metastases in the previous 3 years
Key Trial Info
Start Date :
December 21 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 25 2019
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT03376386
Start Date
December 21 2017
End Date
April 25 2019
Last Update
June 27 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Netherlands Cancer Institute
Amsterdam, Netherlands, 1066CX